Vascular Resections during Curative Surgery for Pancreatic Adenocarcinoma

Abdelkader Boukerrouche*

Department of Digestive Surgery, Hospital of Beni-Messous, University of Algiers, Algiers, Algeria

^*Correspondance to: Abdelkader Boukerrouche 

 PDF  Full Text DOI: 10.25107/2474-1647.2816

Abstract

The Pancreatic Adenocarcinoma (PA) is estimated to become the second leading cancer-related death cause by 2030. At the time of diagnosis, 30% of patients have a locally advanced disease especially vascular involvement Performed firstly in 1973; the benefits of vein resection on survival have been clearly demonstrated by published reports. The vein resection and reconstruction to achieve curative resection is currently considered as standard of care for locally advanced pancreatic tumors with invaded Portal/Superior Mesenteric Vein (PV/SMV). Regarding pancreatic surgery with arterial resection, the survival rates are encouraging compared to systemic treatment alone. Additionally, the development of more systemic therapies has increased the long-term survival after pancreatic resection with arterial resection to nearly the same level after conventional pancreatectomy. Defining better and more useful prognostic, patients-related, and biological criteria is more necessary and hopeful to select the best candidates for curative surgery. Performed in high-volume centers with specific experience in such procedure; complex vascular reconstruction does not significantly increase the operative risk. Furthermore, more designed trials are highly recommended to defining guidelines for pancreatic resection associated with vascular resectionreconstruction for clinical practice. This review focuses on the recent results of vascular resection and reconstruction to achieve curative surgery for pancreatic adenocarcinoma with consideration of new perspectives offered by more developed systemic treatments, during the last five years.

Keywords

Cite the article

Boukerrouche A. Vascular Resections during Curative Surgery for Pancreatic Adenocarcinoma. Clin Surg. 2020; 5: 2816..